Key result
Compound H7 inhibits influenza A replication at ~11 μM by reducing nucleoprotein RNA-binding affinity.
Effect estimate: IC50 10.9 μM
Identification of compound H7 as an inhibitor of influenza A virus replication that targets the Y148 residue in the nucleoprotein RNA-binding groove.
Targeting NP groove residues like Y148 may enable antivirals; leaves open clinical translation pending in vivo and trial data.
Nucleoprotein (NP) is the most abundant type of RNA-binding viral protein in influenza A virus-infected cells and is necessary for viral RNA transcription and replication. Recent studies demonstrated that influenza NP is a valid target for antiviral drug development. The surface of the groove, covered with numerous conserved residues between the head and body domains of influenza A NP, plays a crucial role in RNA binding. To explore the mechanism by which NP binds RNA, we performed a series of site-directed mutagenesis in the RNA-binding groove, followed by surface plasmon resonance (SPR), to characterize the interactions between RNA and NP. Furthermore, a role of Y148 in NP stability and NP-RNA binding was evaluated. The aromatic residue of Y148 was found to stack with a nucleotide base. By interrupting the stacking interaction between Y148 and an RNA base, we identified an influenza virus NP inhibitor, (E, E)-1,7-bis(4-hydroxy-3-methoxyphenyl) -1,6-heptadiene-3,5-dione; this inhibitor reduced the NP's RNA-binding affinity and hindered viral replication. Our findings will be useful for the development of new drugs that disrupt the interaction between RNA and viral NP in the influenza virus.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2016) studied Influenza A virus infection. H7 [(E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] vs. Vehicle control (DMSO) was evaluated on Viral RNA synthesis (M1 viral RNA expression) (IC50 10.9 μM). The compound H7 targeted the Y148 residue of the influenza A virus nucleoprotein, reducing its RNA-binding affinity and inhibiting viral replication with an IC50 of 10.9 μM.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: